GenSight Biologics raises EUR32m in a Series A financing for ophthalmic gene therapy
GenSight Biologics, a biopharmaceutical company focused on the development of ophthalmic therapeutics using gene therapy, has closed a EUR32m Series A financing. The financing was co-led by Novartis Venture Fund, Abingworth, Versant Ventures and Index Ventures. GenSight will use the funds to develop a gene replacement therapy for
